Document Detail

Humoral-targeted immunotherapies in multiple sclerosis.
MedLine Citation:
PMID:  23208729     Owner:  NLM     Status:  MEDLINE    
The continuous improvements of our understanding of the pathophysiological changes that occur in multiple sclerosis (MS) have translated into many novel therapeutic agents at different stages of development. These agents target more specifically the innate or the adaptive immune response. We will review agents available or under development that target the humoral pathways of the adaptive immune response. As such, humoral targeted immunotherapies that are being developed for MS are discussed herein: rituximab, ocrelizumab, and ofatumumab show promise as B-cell depleting agents. Other agents, such as atacicept were suspended during development in MS due to increased inflammatory activity versus the placebo. Although most agents were tested in relapsing-remitting forms of MS, rituximab and ocrelizumab have both been studied in progressive MS, whereas ocrelizumab only is currently moving forward in primary progressive MS trials. We provide an overview of agents available and under development that target the humoral response and include their mechanisms of action, safety profiles, and results of clinical trials.
Sabeen Lulu; Emmanuelle Waubant
Related Documents :
24349509 - Cadmium induces liver cell apoptosis through caspase-3a activation in purse red common ...
23166749 - Paeoniflorin protects against ischemia-induced brain damages in rats via inhibiting map...
23583759 - Erythropoietin administration suppresses human monocyte function in vitro and during th...
24529079 - Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of ...
24307779 - Between scylla and charybdis: the role of the human immune system in the pathogenesis o...
21555119 - Differential expression of pro-inflammatory cytokines, endothelin-1 and nitric oxide sy...
18769199 - Giant papillary conjunctivitis.
3713379 - Comparison of the in vitro cytolytic effect of hepatic, splenic and peritoneal macropha...
20635899 - Immunotherapeutic targets in estrogen deficiency-dependent sjögren's syndrome-related ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics     Volume:  10     ISSN:  1878-7479     ISO Abbreviation:  Neurotherapeutics     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-29     Completed Date:  2013-07-29     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  101290381     Medline TA:  Neurotherapeutics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  34-43     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antibodies, Monoclonal, Murine-Derived / therapeutic use
B-Lymphocytes / drug effects,  immunology
Immunity, Humoral / drug effects*,  immunology
Immunosuppressive Agents / therapeutic use*
Immunotherapy / methods*
Multiple Sclerosis / immunology,  therapy*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Monoclonal, Murine-Derived; 0/Immunosuppressive Agents; 0/ocrelizumab; 0/ofatumumab; 0/rituximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Neuroimaging in mitochondrial disorders.
Next Document:  A molecular photovoltaic system based on Dawson type polyoxometalate and porphyrin formed by layer-b...